MVA-based H5N1 vaccine affords cross-clade protection in mice against influenz a A/H5N1 viruses at low doses and after single immunization

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Kreijtz, Joost H C M ^a   Suezer, Yasemin ^b   de Mutsert, Gerrie ^a   van Amerongen, Geert ^a   Scwantes, Astrid ^b   van den Brand, Judith M A ^a   Fouchier, Ron A M ^a   Löwer, Johannes ^b   Osterhaus, Albert D M E ^a   Sutter, Gerd ^b,c   Rimmelzwaan, Guus F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PAUL EHRLICH INSTITUT   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINIA VACCINE; INFLUENZA VACCINE; RECOMBINANT PROTEIN; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE COMPARISON; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; INFLUENZA; INFLUENZA VIRUS A H5N1; LOW DRUG DOSE; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SURVIVAL RATE; VIRUS REPLICATION; VIRUS STRAIN; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CHEMISTRY; DOG; GENETICS; HUMAN; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LUNG; METHODOLOGY; ORTHOMYXOVIRUS INFECTION; VIROLOGY;

AVIAN INFLUENZA VIRUS; MUS; ORTHOMYXOVIRIDAE;

ANIMALS; DOGS; FEMALE; HUMANS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT PROTEINS; VACCINES;

EID: 70649090329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007790     Document Type: Article

References (40)

1. WHO (2009) Influenza Fact sheet No211, Revised March 2003. Available: http://www.who.int/mediacentre/factsheets/2003/fs211/en/. Accessed 2009 May 08.
2. WHO (2009) New Influenza A(H1N1), Number of laboratory confirmed cases and deaths as reported to WHO, status as of 10 June 2009. Available: http://www.who.int/csr/don/Map_20090610_0800.png. Accessed 2009 June 11.
3. Webby RJ, Webster RG (2003) Are we ready for pandemic influenza? Science 302: 1519-1522.
4. Palese P (2006) Making better influenza virus vaccines? Emerg Infect Dis 12: 61-65.
5. de Wit E, Munster VJ, Spronken MI, Bestebroer TM, Baas C, et al. (2005) Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain. J Virol 79: 12401-12407.
6. Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, et al. (2007) Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25: 6028-6036.
7. Nicolson C, Major D, Wood JM, Robertson JS (2005) Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 23: 2943-2952.
8. Govorkova EA, Kodihalli S, Alymova IV, Fanget B, Webster RG (1999) Growth and immunogenicity of influenza viruses cultivated in Vero or MDCK cells and in embryonated chicken eggs. Dev Biol Stand 98: 39-51; discussion 73-34.
9. Kalbfuss B, Genzel Y, Wolff M, Zimmermann A, Morenweiser R, et al. (2007) Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines. Biotechnol Bioeng 97: 73-85.
10. Nerome K, Kumihashi H, Nerome R, Hiromoto Y, Yokota Y, et al. (1999) Evaluation of immune responses to inactivated influenza vaccines prepared in embryonated chicken eggs and MDCK cells in a mouse model. Dev Biol Stand 98: 53-63; discussion 73-54.
11. Katz JM, Webster RG (1989) Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 160: 191-198.
12. Nwe N, He Q, Damrongwatanapokin S, Du Q, Manopo I, et al. (2006) Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture. BMC Microbiol 6: 16.
13. Crawford J, Wilkinson B, Vosnesensky A, Smith G, Garcia M, et al. (1999) Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 17: 2265-2274.
14. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, et al. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19: 1732-1737.
15. Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD (2008) Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 82: 2565-2569.
16. Lin J, Zhang J, Dong X, Fang H, Chen J, et al. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368: 991-997.
17. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, et al. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370: 580-589.
18. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, et al. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357: 1937-1943.
19. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, et al. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/ Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367: 1657-1664.
20. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, et al. (2002) DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 8: 796-801.
21. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80: 1959-1964.
22. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367: 475-481.
23. Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, et al. (1999) DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 73: 2094-2098.
24. Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, et al. (2009) Recombinant Modified Vaccinia Virus Ankara Expressing the Hemagglutinin Gene Confers Protection against Homologous and Heterologous H5N1 Influenza Virus Infections in Macaques. J Infect Dis 199: 405-413.
25. Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, et al. (2007) Recombinant Modified Vaccinia Virus Ankara-Based Vaccine Induces Protective Immunity in Mice against Infection with Influenza Virus H5N1. J Infect Dis 195: 1598-1606.
26. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12: 1032-1040.
27. Mayr A, Danner K (1978) Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 41: 225-234.
28. Stittelaar KJ, Kuiken T, de Swart RL, van Amerongen G, Vos HW, et al. (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19: 3700-3709.
29. Cosma A, Nagaraj R, Buhler S, Hinkula J, Busch DH, et al. (2003) Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22: 21-29.
30. Drexler I, Staib C, Sutter G (2004) Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol 15: 506-512.
31. Gomez CE, Najera JL, Krupa M, Esteban M (2008) The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 8: 97-120.
32. Sutter G, Staib C (2003) Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3: 263-271.
33. Rimmelzwaan GF, Sutter G (2009) Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines 8: 447-454.
34. Belyakov IM, Moss B, Strober W, Berzofsky JA (1999) Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A 96: 4512-4517.
35. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, et al. (2003) Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77: 799-803.
36. Ramirez JC, Gherardi MM, Rodriguez D, Esteban M (2000) Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 74: 7651-7655.
37. Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, et al. (2006) Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12: 3416-3424.
38. Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD (1998) Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J Virol Methods 74: 57-66.
39. Palmer D, Dowle W, Coleman M, Schild G (1975) Haemagglutination inhibition test. Advanced laboratory techniques for influenza diagnosis Procedural Guide. Atlanta: US Dept. Hlth. ED. pp 25-62.
40. Frank AL, Puck J, Hughes BJ, Cate TR (1980) Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement. J Clin Microbiol 12: 426-432.